Many types of clinical trial to determine the treatment efficiency for lower-limb problems involve assessment of improvements in pain and function level. Unfortunately assessment is often hampered by qualitative results that can vary based on patient mood, physician or even the weather. Consequently, often more patients must participate than would otherwise be necessary to identify the signal amongst the noise. GaitSmart offers a novel solution by enabling quantification of gait.
GaitSmart can provide reliable, accurate, quantitative endpoint measurement to support your pharmacological science.
Quantifying gait can also quantify pain
We have databases drawn from ten years of experience that show gait changes correlate with pain and function. A patient experiencing pain will not walk as well, making changes in gait the perfect surrogate marker. This means that GaitSmart can provide endpoint measurements, allowing quantitative assessment of the efficacy of a particular therapeutic that affects mobility.
GaitSmart allows portable gait analysis. As a result, using GaitSmart opens up a world of quantitative patient feedback in clinical trials involving mobility. For example, during assessment of osteoarthritis treatment, which is currently typically limited to self-reported pain and function assessments.
GaitSmart's digital technology measures the movement of the calf, thigh, knee and hips in three dimensions with extraordinary accuracy (±1 deg, verified at the National Physics Laboratory). Improvement of a few degrees can be detected across 17 different parameters.